213 related articles for article (PubMed ID: 28207159)
1. The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.
Bellanger A; Donini CF; Vendrell JA; Lavaud J; Machuca-Gayet I; Ruel M; Vollaire J; Grisard E; Győrffy B; Bièche I; Peyruchaud O; Coll JL; Treilleux I; Maguer-Satta V; Josserand V; Cohen PA
J Pathol; 2017 May; 242(1):73-89. PubMed ID: 28207159
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
[TBL] [Abstract][Full Text] [Related]
3. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion.
Vendrell JA; Thollet A; Nguyen NT; Ghayad SE; Vinot S; Bièche I; Grisard E; Josserand V; Coll JL; Roux P; Corbo L; Treilleux I; Rimokh R; Cohen PA
Cancer Res; 2012 Jul; 72(14):3593-606. PubMed ID: 22593193
[TBL] [Abstract][Full Text] [Related]
4. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice.
Vollaire J; Machuca-Gayet I; Lavaud J; Bellanger A; Bouazza L; El Moghrabi S; Treilleux I; Coll JL; Peyruchaud O; Josserand V; Cohen PA
Front Pharmacol; 2019; 10():667. PubMed ID: 31275146
[TBL] [Abstract][Full Text] [Related]
5. ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling.
Wang J; Rouse C; Jasper JS; Pendergast AM
Sci Signal; 2016 Feb; 9(413):ra12. PubMed ID: 26838548
[TBL] [Abstract][Full Text] [Related]
6. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
7. ITGBL1 Is a Runx2 Transcriptional Target and Promotes Breast Cancer Bone Metastasis by Activating the TGFβ Signaling Pathway.
Li XQ; Du X; Li DM; Kong PZ; Sun Y; Liu PF; Wang QS; Feng YM
Cancer Res; 2015 Aug; 75(16):3302-13. PubMed ID: 26060017
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
9. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
van der Pluijm G; Sijmons B; Vloedgraven H; Deckers M; Papapoulos S; Löwik C
J Bone Miner Res; 2001 Jun; 16(6):1077-91. PubMed ID: 11393785
[TBL] [Abstract][Full Text] [Related]
10. TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model.
Fritsche H; Heilmann T; Tower RJ; Hauser C; von Au A; El-Sheikh D; Campbell GM; Alp G; Schewe D; Hübner S; Tiwari S; Kownatzki D; Boretius S; Adam D; Jonat W; Becker T; Glüer CC; Zöller M; Kalthoff H; Schem C; Trauzold A
Oncotarget; 2015 Apr; 6(11):9502-16. PubMed ID: 25909161
[TBL] [Abstract][Full Text] [Related]
11. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway.
Katsuno Y; Hanyu A; Kanda H; Ishikawa Y; Akiyama F; Iwase T; Ogata E; Ehata S; Miyazono K; Imamura T
Oncogene; 2008 Oct; 27(49):6322-33. PubMed ID: 18663362
[TBL] [Abstract][Full Text] [Related]
12. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
[TBL] [Abstract][Full Text] [Related]
13. Increased regucalcin gene expression extends survival in breast cancer patients: Overexpression of regucalcin suppresses the proliferation and metastatic bone activity in MDA-MB-231 human breast cancer cells in vitro.
Yamaguchi M; Osuka S; Weitzmann MN; Shoji M; Murata T
Int J Oncol; 2016 Aug; 49(2):812-22. PubMed ID: 27221776
[TBL] [Abstract][Full Text] [Related]
14. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.
Thollet A; Vendrell JA; Payen L; Ghayad SE; Ben Larbi S; Grisard E; Collins C; Villedieu M; Cohen PA
Mol Cancer; 2010 Nov; 9():291. PubMed ID: 21059223
[TBL] [Abstract][Full Text] [Related]
15. Identification of prospective factors promoting osteotropism in breast cancer: a potential role for CITED2.
Lau WM; Weber KL; Doucet M; Chou YT; Brady K; Kowalski J; Tsai HL; Yang J; Kominsky SL
Int J Cancer; 2010 Feb; 126(4):876-84. PubMed ID: 19642106
[TBL] [Abstract][Full Text] [Related]
16. ZNF217 is associated with poor prognosis and enhances proliferation and metastasis in ovarian cancer.
Li J; Song L; Qiu Y; Yin A; Zhong M
Int J Clin Exp Pathol; 2014; 7(6):3038-47. PubMed ID: 25031722
[TBL] [Abstract][Full Text] [Related]
17. Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
Taipaleenmäki H; Browne G; Akech J; Zustin J; van Wijnen AJ; Stein JL; Hesse E; Stein GS; Lian JB
Cancer Res; 2015 Apr; 75(7):1433-44. PubMed ID: 25634212
[TBL] [Abstract][Full Text] [Related]
18. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.
Krig SR; Miller JK; Frietze S; Beckett LA; Neve RM; Farnham PJ; Yaswen PI; Sweeney CA
Oncogene; 2010 Oct; 29(40):5500-10. PubMed ID: 20661224
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.
Westbrook JA; Wood SL; Cairns DA; McMahon K; Gahlaut R; Thygesen H; Shires M; Roberts S; Marshall H; Oliva MR; Dunning MJ; Hanby AM; Selby PJ; Speirs V; Mavria G; Coleman RE; Brown JE
J Pathol; 2019 Mar; 247(3):381-391. PubMed ID: 30426503
[TBL] [Abstract][Full Text] [Related]
20. Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells.
Taipaleenmäki H; Farina NH; van Wijnen AJ; Stein JL; Hesse E; Stein GS; Lian JB
Oncotarget; 2016 Nov; 7(48):79032-79046. PubMed ID: 27738322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
